Anti-CD20 should be the first-line treatment in high-risk membranous nephropathy
Clinical Kidney Journal · 31.08.2023 · 16 (9) · 1420-1425
DOI: 10.1093/ckj/sfad075 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Kidney Journal, online erschienen am 10.04.2023. Verfasst von Ladan Zand und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Genentech.
Abstract (Originalsprache)
Membranous nephropathy (MN) is a common cause of nephrotic syndrome (NS) in adults and if untreated can progress to endstage kidney disease. Factors considered to place a patient at high or very high risk for progression include elevated serum creatinine at baseline, declining kidney function, persistent heavy proteinuria (>8 g/24 h), or persistent NS, presence of life-threatening complications related to NS (such as venous thromboembolic events), or very high anti-PLA2R antibody titers (>150 RU/ml). Patients who are at high or very high risk of progression should be treated with immunosuppression therapy to induce remission of proteinuria and to avoid progressive loss of kidney function. Traditional forms of immunosuppression for patients with MN have included the use of cyclic courses of corticosteroids with cyclophosphamide or calcineurin inhibitors. These forms of therapy are associated with significant toxicity, e.g. corticosteroids (infections, diabetes, weight gain), cyclophosphamide (infertility, severe leukopenia, malignancy), and calcineurin inhibitors (hypertension, nephrotoxicity). The introduction of anti-CD20+ B-cell therapies in the late 1990s has changed the landscape. In this article we will argue that anti-CD20+ B therapy should be the treatment of choice for patients at high/very high risk of progression when considering its efficacy and side-effect profile.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA.
ORCID-Profile: Fernando C Fervenza
Förderung
- Genentech
Zitieren
APA
Zand, L., & Fervenza, F. C. (2023). Anti-CD20 should be the first-line treatment in high-risk membranous nephropathy. Clinical Kidney Journal, 16(9), 1420-1425. https://doi.org/10.1093/ckj/sfad075
Vancouver
Zand L, Fervenza FC. Anti-CD20 should be the first-line treatment in high-risk membranous nephropathy. Clinical Kidney Journal. 2023;16(9):1420-1425. doi:10.1093/ckj/sfad075
BibTeX
@article{Zand2023,
author = {Zand, Ladan and Fervenza, Fernando C},
title = {Anti-CD20 should be the first-line treatment in high-risk membranous nephropathy},
journal = {Clinical Kidney Journal},
year = {2023},
volume = {16},
number = {9},
pages = {1420--1425},
doi = {10.1093/ckj/sfad075}
}
EUVIMED